DNA ploidy, nuclear size, proliferation index and DNA-hypomethylation in ovarian cancer

Gynecologic Oncology

Volumn 121, Issue 1, 2011, Pages 24-31

  Zeimet, Alain G ^a   Fiegl, Heidi ^a   Goebel, Georg ^a   Kopp, Francis ^b   Allasia, Claude ^b   Reimer, Daniel ^a   Steppan, Ilona ^a   Mueller Holzner, Elisabeth ^a   Ehrlich, Melanie ^c   Marth, Christian ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b HÔPITAL NORD   (France)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

DNA ploidy; DNA hypomethylation; Nuclear area; Ovarian cancer; Proliferation index

Indexed keywords

ADULT; AGE; AGED; ANEUPLOIDY; ARTICLE; CANCER SURVIVAL; CHROMOSOME 1; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; FEMALE; GENOME; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MUCINOUS CARCINOMA; NUCLEAR SIZE; NUCLEOTIDE SEQUENCE; ONCOLOGICAL PARAMETERS; OVARY CANCER; OVERALL SURVIVAL; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROLIFERATIVE INDEX;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; CELL GROWTH PROCESSES; CELL NUCLEUS SIZE; CHROMOSOMES, HUMAN, PAIR 1; CYSTADENOCARCINOMA, SEROUS; DISEASE-FREE SURVIVAL; DNA METHYLATION; DNA, NEOPLASM; FEMALE; GENOMIC INSTABILITY; HUMANS; LONG INTERSPERSED NUCLEOTIDE ELEMENTS; MIDDLE AGED; OVARIAN NEOPLASMS; PLOIDIES; YOUNG ADULT;

EID: 79952817425     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.12.332     Document Type: Article

References (29)

1. Lipsanen V, Leinonen P, Alhonen L, Janne J. Hypomethylation of ornithine decarboxylase gene and erb-A1 oncogene in human chronic lymphatic leukemia. Blood 1988;72:2042-4. (Pubitemid 19030896)
2. Hanada M, Delia D, Aiello A, Stadtmauer E, Reed JC. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 1993;82:1820-8. (Pubitemid 23278773)
3. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998;72:141-96. (Pubitemid 27435555)
4. Ovchinnikov I, Rubin A, Swergold GD. Tracing the LINEs of human evolution. Proc Natl Acad Sci USA 2002;99:10522-7.
5. Eden A, Gaudet F, Waghmare A, Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003;300:455. (Pubitemid 36444319)
6. Widschwendter M, Jiang G, Woods C, Müller HM, Fiegl H, Goebel G, et al. DNA hypomethylation and ovarian cancer biology. Cancer Res 2004;64:4472-80. (Pubitemid 38856918)
7. Blumenfeld D, Braly PS, Ben-Ezra J, Klevecz RR. Tumor DNA content as a prognostic feature in advanced epithelial ovarian carcinoma. Gynecol Oncol 1987;27:389-402.
8. Friedlander ML, Hedley DW, Swanson C, Russell P. Prediction of long-termsurvival by flow cytometric analysis of cellular DNA content in patients with advanced ovarian cancer. J Clin Oncol 1988;6:282-90. (Pubitemid 18065932)
9. Trope C, Kaern J, Hogberg T, Abeler V, Hagen B, Kristensen G, et al. Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument. Ann Oncol 2000;11:281-8. (Pubitemid 30214664)
10. Bernabei VM, Miller DS, Bauer KD, Murad TM, Rademaker AW, Lurain JR. Flow cytometric evaluation of epithelial ovarian cancer. Am J Obstet Gynecol 1990;162:1584-90.
11. Pfisterer J, Kommoss F, Sauerbrei W, Renz H, du Bois A, Kiechle-Schwarz M, et al. Cellular DNA content and survival in advanced ovarian carcinoma. Cancer 1994;74:2509-15.
12. ColeyHM, Sargent JM, Titley J, TaylorCG. Lack of prognostic significance of ploidy and S-phasemeasurements in advanced ovarian cancer. Anticancer Res 1999;19:2111-6.
13. Kimmig R, Wimberger P, Hillemanns P, Kapsner T, Caspari C, Hepp H. Multivariate analysis of the prognostic significance of DNA-ploidy and S-phase fraction in ovarian cancer determined by flow cytometry following detection of cytokeratin-labeled tumor cells. Gynecol Oncol 2002;84:21-31. (Pubitemid 34056461)
14. Yusup A, Kanamaru H, Aoki Y, Saikawa S, Moriyama N, Oyama N, et al. Prognostic value of nuclear area index in patients with bladder cancer. Int J Urol 2004;11:374-8. (Pubitemid 38858933)
15. Bol MG, Baak JP, Rep S, Marx WL, Kruse AJ, Bos SD, et al. Prognostic value of proliferative activity and nuclear morphometry for progression in TaT1 urothelial cell carcinomas of the urinary bladder. Urology 2002;60:1124-30. (Pubitemid 35447592)
16. Klein M, Graf AH, Rosen A, Lahousen M, Hacker GW. Tumor progression, histologic grading and DNA-ploidy as predictive factors of lymphogenous metastasis in primary carcinoma of the Fallopian tube. Cancer Lett 2002;177:209-14. (Pubitemid 34127923)
17. Colomb E, Kopp F, Spyratos F, Martin PM. Cell-cycle studies by multiparametric automatic scanning of topographically preserved cells in culture. Cytometry 1989;10:263-72. (Pubitemid 19107482)
18. Charpin C, Martin PM, Lissitzky JC, Jacquemier J, Kopp F, Pourreau-Schneider N, et al. Estrogen receptor immunocytochemical assay (ERICA) and laminin detection in 130 breast carcinomas and computerized (Samba 200) multiparametric quantitative analysis on tissue sections. Bull Cancer 1986;73:651-64. (Pubitemid 17219669)
19. van Velthoven R, Petein M, Oosterlinck WJ, Zandona C, Zlotta A, Van der Meijden AP, et al. Image cytometry determination of ploidy level, proliferative activity, and nuclear size in a series of 314 transitional bladder cell carcinomas. Hum Pathol 1995;26:3-11.
20. Weisenberger DJ, Campan M, Long TI, Kim M, Woods C, Fiala E, et al. Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res 2005;33:6823-36. (Pubitemid 41830488)
21. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000;28:E32.
22. Ehrlich M, Hopkins NE, Jiang G, Dome JS, Yu MC, Woods CB, et al. Satellite DNA hypomethylation in karyotyped Wilms' tumors. Cancer Genet Cytogenet 2003;141:97-105. (Pubitemid 36269208)
23. Narayan A, Ji W, Zhang XY, Marrogi A, Graff JR, Baylin SB, et al. Hypomethylation of pericentromeric DNA in breast adenocarcinomas. Int J Cancer 1998;77:833-8. (Pubitemid 28378129)
24. Esteller M, Herman JG. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol 2002;196:1-7.
25. Nan X, Campoy FJ. BirdA. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 1997;88:471-81.
26. Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N, et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998;19:187-91. (Pubitemid 28248804)
27. Jintaridth P, Mutirangura A. Distinctive patterns of age-dependent hypomethylation in interspersed repetitive sequences. Physiol Genomics 2010 Epub ahead of print.
28. Baba Y, Huttenhower C, Nosho K, Tanaka N, Shima K, Hazra A, et al. Epigenomic diversity of colorectal cancer indicated by LINE1 methylation in a database of 869 tumors. Mol Cancer 2010;9:125.
29. Wilhelm CS, Kelsey KT, Butler R, Plaza S, Gagne L, Zens MS, et al. Implications of LINE1 methylation for bladder cancer risk in women. Clin Cancer Res 2010;16:1682-9.